Clinical Trials
8 trialsNCT02530619 2021-05-26
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
Northwestern University
Phase NA Unknown
NCT01154816 2020-05-13
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Children's Oncology Group
Phase 2 Completed
NCT02560025 2020-05-05
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Massachusetts General Hospital
Phase 2 Completed
NCT00697346 2019-05-31
Study of MLN8237 in Participants With Advanced Hematological Malignancies
Takeda
Phase 1 Completed
NCT00830518 2018-05-11
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Takeda
Phase 2 Completed
NCT01567709 2018-04-11
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01779843 2017-02-17
Alisertib for Acute Myeloid Leukemia
Massachusetts General Hospital
Phase 1 Completed
NCT01466881 2016-03-10
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed